WEED Inc. (USA) acquires Hempirical Genetics LLC, with over 250 proprietary cannabis and hemp strains for $750,000.00

HEMP BioSciences Inc., a wholly owned division of WEED Inc., will oversee our genetics programs. Panama Red, Acapulco Gold, Red Bud Colombian, and Santa Marta Gold top the list.

TUCSON, AZ /ACCESSWIRE/July 20, 2022/ WEED, Inc. (OTCQB:BUDZ) (“WEED” or the “Company”), a global cannabis and hemp bioresearch company based in the United States, focused on the development and application of cannabis-derived compounds for the treatment of human diseases and Animals, today announced that it has acquired 100% of Hempirical Genetics, LLC, for 2 million common shares valued at $0.25 per share and $250,000 cash over 4 years. One million shares and $10,000.00 were paid upon signing this agreement. The company views the acquisition as a game changer, which will help ensure WEED’s growth and dedication to new discoveries in the field of medical cannabis. WEED researchers will now have a plethora of options to discover the REAL benefits of the Cannabaceae plant.

WEED, Inc., Wednesday, July 20, 2022, press release photo

Glenn E. Martin, CEO of WEED, Inc., says, “Our teams in the United States, Australia and Israel are thrilled that a pipeline of original ‘Landrace’ strains from the 1970s can now be transferred to clinical trials. and product development. for the global market. WEED now boasts over 15 original, virgin, F-1 grade “PURE” cannabis strains, including Panama Red, Acapulco Gold, Red Bud Colombian, and Santa Marta Gold. Our newly acquired inventory includes over 30 CBD & CBG strains as WEED believe that multiple combinations of precise cannabinoid strains will create the entourage effect to achieve the desired medical outcome. Ultimately, WEED plans to bring our desired unique strains to adult-use markets once the “law of the land” brings back the Freedoms lost over 70 years ago.”

Mr. Jeffery Miller, the former owner of Hempirical Genetics, will lead the charge of strain and product development as the new CEO of HEMP BioScience. Mr. Martin comments: “I have known Jeff for half a century. His horticultural skills and dedication to the Canabacae plant are second to none. I am extremely proud to have my old friend and his team (including the strains WEED purchased in the acquisition), who we believe will bring success year after year for the benefit of WEED shareholders. »

Mr. Jeffery Miller comments, “I have known Glenn Martin for more than 50 years and I am honored to lead HEMP BioSciences to develop our genetic studies. My goal is to bring the most potent, high quality THC and hemp products to market at an affordable price. “Double the quality, half the price” should be the mantra of the cannabis industry, while creating diversity and equality in the cannabis industry. Our veterans have been very neglected, and I’m looking to develop low-cost or no-cost veterinary programs, which I know is a priority for Glenn and mine.”

“WEED is looking to re-establish its R&D in clinical trials domestically as well as in Israel working with sister company, WEED Israel Cannabis Ltd. on product development and educational tools for doctors, practitioners of health and the public. Jeff will be the key coordinator for our studies globally.” says Glenn E. Martin, “Our primary focus now is to create a pipeline of highly effective products, both pharmaceutical and non-pharmaceutical, to further the knowledge and uses of cannabis and its derivative forms, high-potency compounds THC to CBD and CBG compounds. Research is key to long-term success. An informed customer is your best patient. Martin continues; “We believe that the majority of discoveries in cannabis and hemp are yet to be found. We live in exciting times! Jeffery Miller and WEED seek to change the mindset of global health in favor of natural remedies.”

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations governing the cannabis industry in the United States. Although legal in some states, cannabis remains a Schedule I drug under the United States Controlled Substances Act, making it illegal under federal law in the United States, among other things, cultivation, distribution or possession of cannabis. Financial transactions involving proceeds generated by, or intended to promote, commercial cannabis-related activities in the United States may form the basis of prosecution under applicable United States federal money laundering laws. Investors should carefully read the risk factors and information contained in our offering circular before making a decision to invest in our company.

Forward-looking information

This press release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information in this press release can be identified by the use of words such as “may”, “could”, “could”, “will”, “likely”, “expect”, “anticipate”. , “believes”, “intends”, “plans”, “expects”, “projects”, “estimates”, “prospects” and other similar expressions, and include statements regarding future revenues and profits. Forward-looking information is not a guarantee of future results. performance and is based on a number of management’s estimates and assumptions in light of management’s experience and perception of trends, current conditions and expected developments, as well as other relevant factors in the circumstances, including assumptions regarding current and future market conditions, the current and future regulatory environment and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on forward-looking information as the Company cannot guarantee that it will prove to be accurate. Actual results and developments may differ materially from those contemplated by such statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements contained in this press release are made as of the date of this press release. The Company disclaims any intention or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Legal notice

The information is provided for convenience only, does not constitute investment advice, and should not be relied upon in considering an investment in WEED, Inc. No representations or warranties, express or implied, are made as to the accuracy or completeness of the information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related documents, as well as independent investor research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will obtain or are likely to obtain favorable results, make any profit or be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

WEED, Inc., Wednesday, July 20, 2022, press release photo

WEED, Inc., Wednesday, July 20, 2022, press release photo

Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
[email protected]

THE SOURCE: WEEDS, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/709193/WEED-Inc-USA-Acquires-Hempirical-Genetics-LLC-wOver-250-Proprietary-Cannabis-Hemp-Strains-for-75000000

Comments are closed.